Related Experiment Video
Updated: May 14, 2025
06:02
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
88
Fibrotic Pulmonary Sarcoidosis-From Pathogenesis to Management.
Ewa Łyżwa1, Jacek Wakuliński2, Monika Szturmowicz1
11st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Journal of Clinical Medicine
|April 12, 2025
Summary
Sarcoidosis can lead to pulmonary fibrosis, a serious complication. Understanding its immunological basis and multidisciplinary management is key for better patient outcomes.
Area of Science:
- Immunology
- Pulmonology
- Pathology
Background:
- Sarcoidosis is a multisystem granulomatous disease of unknown cause.
- Pulmonary fibrosis is a significant cause of mortality in sarcoidosis.
- Immunological mechanisms driving fibrosis are increasingly understood.
Purpose of the Study:
- To review current knowledge on fibrotic pulmonary sarcoidosis.
- To discuss factors influencing fibrosis development and prognosis.
- To outline current and potential treatment strategies.
Main Methods:
- Literature review of recent studies on sarcoidosis and pulmonary fibrosis.
- Analysis of immunological mechanisms involved in fibrosis.
- Evaluation of clinical, biomarker, imaging, and functional data for management.
Main Results:
- Fibrosis pathogenesis involves altered lymphocyte and macrophage activity.
- Imbalances in matrix metalloproteinases and their inhibitors contribute to fibrosis.
- Optimal management requires a multidisciplinary approach considering various clinical factors.
Conclusions:
- Fibrotic pulmonary sarcoidosis necessitates a comprehensive management strategy.
- Further research is needed to establish consensus on antifibrotic agent use.
- Understanding disease mechanisms is crucial for improving prognosis and treatment.
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
193
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
193
01:28Pulmonary Tuberculosis II
201
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
201
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:24Cystic Fibrosis: Management
110
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
110
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
136
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
136